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Abstract
Background: Patients with type 2 diabetes vary greatly with respect to degree of obesity at time of diagnosis. To address
the heterogeneity of type 2 diabetes, we characterised patterns of change in body mass index (BMI) and other
cardiometabolic risk factors before type 2 diabetes diagnosis.
Methods and Findings: We studied 6,705 participants from the Whitehall II study, an observational prospective cohort
study of civil servants based in London. White men and women, initially free of diabetes, were followed with 5-yearly clinical
examinations from 1991–2009 for a median of 14.1 years (interquartile range [IQR]: 8.7–16.2 years). Type 2 diabetes
developed in 645 (1,209 person-examinations) and 6,060 remained free of diabetes during follow-up (14,060 person-
examinations). Latent class trajectory analysis of incident diabetes cases was used to identify patterns of pre-disease BMI.
Associated trajectories of cardiometabolic risk factors were studied using adjusted mixed-effects models. Three patterns of
BMI changes were identified. Most participants belonged to the ‘‘stable overweight’’ group (n= 604, 94%) with a relatively
constant BMI level within the overweight category throughout follow-up. They experienced slightly worsening of beta cell
function and insulin sensitivity from 5 years prior to diagnosis. A small group of ‘‘progressive weight gainers’’ (n= 15)
exhibited a pattern of consistent weight gain before diagnosis. Linear increases in blood pressure and an exponential
increase in insulin resistance a few years before diagnosis accompanied the weight gain. The ‘‘persistently obese’’ (n= 26)
were severely obese throughout the whole 18 years before diabetes diagnosis. They experienced an initial beta cell
compensation followed by loss of beta cell function, whereas insulin sensitivity was relatively stable. Since the
generalizability of these findings is limited, the results need confirmation in other study populations.
Conclusions: Three patterns of obesity changes prior to diabetes diagnosis were accompanied by distinct trajectories of
insulin resistance and other cardiometabolic risk factors in a white, British population. While these results should be verified
independently, the great majority of patients had modest weight gain prior to diagnosis. These results suggest that
strategies focusing on small weight reductions for the entire population may be more beneficial than predominantly
focusing on weight loss for high-risk individuals.
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Introduction
Obesity is a well-established risk factor for type 2 diabetes;
however, it is well-known that patients with type 2 diabetes vary
greatly with respect to degree of adiposity at time of diagnosis
[1–3]. Thus, a better understanding of the heterogeneity of
diabetes is important for improving disease prevention and
treatment. Recent studies have described trajectories in plasma
glucose, insulin sensitivity, beta cell function, and subclinical
inflammation related to diabetes before the disease is diagnosed
[4–6]. These population-level growth curves contribute to
aetiological and pathophysiological understanding, but may
somewhat oversimplify the complex and heterogeneous disease
mechanisms responsible for type 2 diabetes. To facilitate stratified,
targeted interventions, identification of population subgroups with
similar risk factor patterns seems essential. One way of identifying
such groups is to use data-driven statistical methods, such as latent
class trajectory analysis [7]. This method identifies distinct classes
or subgroups of people who are homogeneous with respect to the
development of a given risk factor over time, but heterogeneous as
compared with other groups. Although latent class trajectory
analysis has been widely used in criminology and behavioural
research [8,9], it is new to health research [10,11] and has only
very recently been applied in a study of diabetes patients [12], but
not in relation to diabetes aetiology.
In this study, we aimed to identify different patterns of obesity
development over a period of 18 years in a population initially free
of diabetes. In addition, we examined trajectories of other
metabolic risk factors accompanying each pattern of obesity
development.
Methods
Ethics Statement
The Whitehall II study was reviewed and approved by the
University College London Ethics Committee (85/0938). Written
informed consent was obtained from each participant at each
phase. The study was conducted according to the principles of the
Helsinki Declaration.
Study Participants
This study uses data from the longitudinal Whitehall II cohort
of non-industrial British civil servants. In the original study, a total
of 10,308 participants (6,896 men and 3,412 women aged 35–55
years) of mainly white ethnicity who worked in London offices of
20 departments were recruited between 1985 and 1988 (phase 1)
and followed at eight subsequent phases ,2.5 years apart. All
study phases included a questionnaire, and every second phase
(,5 years apart) also included a clinical health examination
(phases 1, 3, 5, 7, and 9). In the Whitehall II cohort 6,057 men and
2,758 women participated at phase 3 (1991–1993); 5,473 men and
2,397 women at phase 5 (1997–1999); 4,893 men and 2,074
women at phase 7 (2002–2004); and 4,759 men and 2,002 women
at phase 9 (2007–2009). The Whitehall II study is described in
detail elsewhere [13].
Phase 3 (1991–1993) was the first phase when an oral glucose
tolerance test (OGTT) was performed. Therefore, we did not use
data from phase 1. With the last follow-up being the phase 9
examination in 2008–2009, this study was based on 9,181 (89.1%)
white participants. From these, we excluded 830 (9.0%) partici-
pants who were lost to follow-up prior to phase 3, 211 (2.3%)
participants with prevalent diabetes at phase 3 (51% based on
OGTT and 49% based on a diabetes diagnosis outside the study),
776 (8.5%) participants for which diabetes status could not be
assessed at any phase in the study, and another 659 (7.2%) with no
measurement of body mass index (BMI) throughout the study.
At phases 3, 5, 7, and 9 a standard 2-hour 75 g OGTT was
performed in the morning after an overnight fast ($8 hours of
fasting). For a subset of participants, the OGTT was administered
in the afternoon after a light fat-free breakfast ($5 hours of
fasting). OGTT measurements for participants with less than
8 hours of fasting were excluded from the analysis. Diabetes was
diagnosed by a doctor outside the study (43.1%) or at screening by
OGTTs (56.9%). Screen-detected diabetes was ascertained
throughout follow-up by OGTTs administered every 5 years
and defined according to the OGTT criteria defined by the World
Health Organization (WHO) [14].
Thus, the final sample included 6,705 participants (73.0% of the
original sample of white ethnicity) with a median follow-up time of
14.1 years (interquartile range [IQR]: 8.7–16.2 years) and 15,269
person-examinations. We identified 645 (9.6%, 1,209 person-
examinations) cases of incident diabetes by phase 9.
A flow diagram of the participants included at each phase is
shown in Figure 1.
Study Procedures and Calculations
Weight, height, and waist circumference were measured
according to standard protocols [13] at phases 3, 5, 7, and 9.
Systolic and diastolic blood pressure was measured by manual
random zero sphygmomanometer at phases 3 and 5 and by
OMRON HEM 907 at phases 7 and 9. Data on ethnicity,
smoking status, and family history of diabetes were collected by
questionnaire at each phase. During all phases of the study, blood
samples were handled according to standardized procedures.
Blood glucose was measured with the glucose oxidase method [4],
and serum insulin was measured with an in-house human insulin
radioimmunoassay (phase 3) and a DAKO insulin ELISA kit
(DakoCytomation Ltd) in later phases [15]. Serum triglycerides,
total cholesterol, and high-density lipoprotein (HDL) cholesterol
were measured using automated enzymatic colorimetric methods
at all phases. Interleukin 1 receptor antagonist (IL-1Ra) and total
adiponectin serum concentrations were measured with the
Quantikine ELISA kit (R&D Systems) in a diabetes case-cohort
sample [5,6]. We used Friedewald’s formula to calculate low-
density lipoprotein (LDL) cholesterol [16]. The homeostasis model
assessment was used to estimate b-cell function (HOMA-%B) and
insulin resistance (HOMA-IR) [17]. The absolute 8-year risk of
developing type 2 diabetes was calculated in all participants using
the Framingham diabetes risk score [18]. Moreover, the
Framingham cardiovascular disease (CVD) risk score was used
to estimate absolute 10-year risk of developing CVD [19].
Statistical Analysis
For comparison of characteristics between groups we used chi-
square test for categorical variables and t-tests for continuous data.
A level of significance of 5% was used.
Latent class trajectory analysis. The observation period
for retrospective trajectories started at the date of diagnosis for
those who developed diabetes, and at the last screening or
questionnaire phase for those not developing diabetes (year 0).
Date of diabetes diagnosis was set to the date of the OGTT for
screen-detected diabetes or to the midpoint between dates of first
self-reported diabetes and last diabetes-free screening for patients
diagnosed by a doctor outside the study.
The latent class trajectory analysis was performed in the
population developing diabetes. The model was specified as a
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linear mixed-effects model with BMI as the dependent variable. The
mixed-effects model specification was used to account for the likely
correlation of repeated measurements within the same participant.
In the analysis we adjusted for age, sex, and study phase in order to
identify latent groups with a different BMI development over time
not attributed to differences in age, sex, or study phase.
We used a cubic specification for trajectory shape, i.e., both
linear, quadratic, and cubic terms for the time before diabetes
diagnosis was entered as covariates in the model. We assumed the
effects of confounders (age, sex, and study phase) to be the same
for all latent classes and looked for latent classes with different
regression parameters for time. A linear term for time before
diagnosis was used to specify the random effects of the model, i.e.,
the individual variation around the mean trajectory (of the
individual’s latent class).
The ‘‘hlme’’ function in the ‘‘lcmm’’ package in R version 9.15.2
(The R foundation for Statistical Computing) was used to fit the
model http://cran.r-project.org/web/packages/lcmm/lcmm.pdf.
hlme (BMI , t + t2 + t3 + age + sex + phase,
mixture =, t + t2 + t3,
random = , t,
subject = ‘id’,
ng = 3,
data = data)
The number of latent classes needs to be specified a priori. The
optimal number of latent classes to describe data is assessed by
comparing the fit of models with different number of latent classes.
Figure 1. Flow diagram of the participants included at each phase.
doi:10.1371/journal.pmed.1001602.g001
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With a prior requirement of at least 2% of the diabetes population
in each group to warrant clinical relevance, we used the Bayesian
Information Criterion (BIC) to evaluate the models and selected
the number of classes for which the model had the lowest BIC. In
this study, three latent classes were identified.
Upon the model fit, a posterior probability of membership to
each of the identified latent classes was calculated for each
participant, who then was assigned exclusively to the class for
which the highest probability was obtained. This class-allocation
was used in the subsequent analyses of the accompanying
cardiometabolic risk factors.
For each identified BMI group, trajectories of the following
outcomes were followed backwards in time to the first clinical
examination: waist circumference; systolic and diastolic blood
pressure; total, HDL and LDL cholesterol; triglycerides; fasting
and 2-hour plasma glucose; fasting and 2-hour serum insulin;
HOMA-%B and HOMA-IR; the Framingham diabetes and CVD
risk scores; adiponectin and IL-1Ra. Prior to analysis, outcomes
with highly skewed distributions were log-transformed (fasting and
2-hour serum insulin, HOMA-%B and HOMA-IR, adiponectin
and IL-1Ra). For most determinants #5% of the values were
missing. For plasma glucose and serum insulin the proportions of
missing values were slightly higher (7%–18%). The case-cohort
sample with measurements of adiponectin and IL-1Ra covered 66%
of diabetes cases and 41% of diabetes-free individuals in this study.
We used linear mixed-effects models to estimate trajectories for
each group. For those developing diabetes, time dependence was
allowed to vary across the BMI groups. Quadratic and cubic terms
for time were included in the three BMI groups when significant
(two-sided 5% significance level). For individuals not developing
diabetes, year 0 is merely a time point in a normal life course, and
we therefore fitted the trajectories by linear models. All analyses
were adjusted for age, sex, and study phase. Analyses of lipids were
further adjusted for lipid-lowering treatment, and analyses of
blood pressure were further adjusted for anti-hypertensive
treatment. We tested pair-wise differences in growth curves
between the BMI groups using the F-test by comparing the curve
of contrasts between two BMI subgroups to a straight line with
zero slope and through the origin (two-sided 5% significance level).
Provided p-values therefore relate to curve differences in slope,
intercept, or both.
Statistical analyses were performed in R version 9.15.2 (The R
Foundation for Statistical Computing) and SAS version 9.2 (SAS
Institute).
Data Sharing
Whitehall II data, protocols, and other metadata are available to
the scientific community. Please refer to the Whitehall II data sharing
policy on: www.ucl.ac.uk/whitehallII/data_sharing/index.htm.
Results
Patterns of Obesity Development
We identified three distinct patterns of BMI development prior
to diabetes diagnosis (Figure 2A). The latent class group,
representing the majority of individuals who developed diabetes,
was characterised by an average BMI in the overweight range
during the entire follow-up (n=604). This group had an average
weight gain of 2.3 BMI units during 18 years of follow-up and was
labelled ‘‘stable overweight,’’ because mean BMI was within the
overweight category as defined by the WHO (average BMI at time
of diagnosis: 28.1 kg/m2). Another group had an average BMI in
the overweight range more than 15 years before diagnosis, an
early weight gain of 8.6 BMI units from 18 to 10 years before
diagnosis, then stable BMI in the obese range until 4–5 years
before diagnosis. Thereafter, BMI increased to morbid obesity
(mean BMI of 41.1 kg/m2), totalling a weight gain of 16.1 BMI
units during follow-up. This group was termed ‘‘progressive weight
gainers’’ (n=15). The third group (n=26), labelled ‘‘persistently
obese,’’ was characterised by BMI in the obese range more than
15 years before diagnosis of diabetes (average BMI of 32.7 kg/m2),
and with persistent obesity until the time of diagnosis. This group
had an average weight gain of 6.0 BMI units during the 18 years of
follow-up.
The average BMI development in the reference group not
developing diabetes was only 1.7 BMI units during the 18 years of
follow-up, from 24.5 kg/m2 to 26.2 kg/m2.
The trajectories of waist circumference (Figure 2B) followed those
of BMI for the three BMI trajectory groups with the stable
overweight group being significantly different from the progressive
weight gainers (p,0.001) and the persistently obese (p,0.001). The
trajectories of waist circumference for the progressive weight gainers
and the persistently obese did not differ significantly (p$0.13).
Trajectories of Blood Pressure and Lipids
Trajectories of diastolic blood pressure did not differ between
the progressive weight gainers and the persistently obese groups
(Figure 2D, p=0.18). Individuals with stable overweight exhibited
near-normal diastolic blood pressure during follow-up (Figure 2D,
p,0.001 versus progressive weight gainers, p=0.04 versus
persistently obese), although systolic blood pressure did not differ
significantly between the groups (Figure 2C, p$0.17). Plasma lipid
levels showed a stable pattern towards diabetes diagnosis in the
stable overweight group (Figure 3A–3D). LDL cholesterol levels
were lower among the progressive weight gainers than among the
group of stable overweight (Figure 3C, p=0.010). The progressive
weight gainers did not differ from the other groups with respect to
other blood lipids (Figure 3, p$0.07 for all). HDL cholesterol was
significantly lower during follow-up in the persistently obese
compared with the stable overweight group (Figure 3B, p=0.03),
whereas triglyceride levels were higher (Figure 3D, p=0.003).
Trajectories of Insulin and Glucose Metabolism
Trajectories of fasting and 2-hour plasma glucose concentra-
tions were similar in all three groups up to a few years before
diagnosis at which time point the progressive weight gainers
experienced a steep increase (Figure 4A and 4B, p,0.02 for all).
Fasting serum insulin concentrations increased exponentially in
the group of progressive weight gainers (Figure 4C, p#0.001
versus stable overweight). In contrast, fasting serum insulin
concentrations were near-normal in the stable overweight group
(Figure 4C, p,0.001 versus both other groups). No significant
differences in trajectories of 2-hour serum insulin concentration
were observed between groups (Figure 4D, p$0.13 for all).
Of interest, the change in fasting serum insulin in the
progressive weight gainers was not reflected in the measure of
beta cell function, which was stable during follow-up, but at a
higher level as compared with the stable overweight group
(Figure 5A, p,0.001). The shape of beta cell function seemed
different in the persistently obese than in the other groups with a
classic pattern of beta cell compensation reaching maximum 8
years before diagnosis; however, this difference did not reach
statistical significance (p$0.12).
In general, the trajectories of insulin resistance followed those of
BMI. The stable overweight group had lower levels of insulin
resistance during follow-up than either of the other groups
(Figure 5B, p#0.007 for both). Insulin resistance increased rapidly
during the last 2–3 years prior to diagnosis in the progressive
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weight gainers compared with the stable overweight group
(Figure 5B, p,0.001). In the persistently obese group, insulin
resistance increased rapidly more than 10 years before diagnosis,
became stable until a few years before diagnosis, and then
increased again (Figure 5B, p=0.007 versus stable overweight).
Trajectories of Estimated Diabetes and CVD Risk
Interestingly, the calculated 8-year diabetes risk declined
towards diabetes diagnosis in the large stable overweight group
(Figure 5C, p,0.001 versus both other groups), whereas calculated
diabetes risk was higher in the persistently obese group (Figure 5C,
p,0.001 versus stable overweight group). Despite the low
estimated diabetes risk, the calculated 10-year risk of CVD
increased rapidly during the last years prior to diagnosis in the
stable overweight and persistently obese groups as compared with
the group of progressive weight gainers who experienced a linear
increase in calculated CVD risk during follow-up (Figure 5D,
p,0.001 versus both groups).
Trajectories of Adiponectin and IL-1Ra
We found no differences in adiponectin trajectories between the
groups (p.0.31), but the levels of IL-1Ra increased exponentially
in the group of progressive weight gainers as compared with the
other groups (p,0.002 for both) (Figure 6A and 6B).
Figure 2. Trajectories for a hypothetical male of 60 years at time 0 of body mass index (A), waist circumference (B), systolic blood
pressure (C), and diastolic blood pressure (D) from 18 years before time of diagnosis/last examination. Trajectories for blood pressure
represent a person not on anti-hypertensive treatment. Solid lines indicate estimated trajectories for each group and dashed lines are 95% confidence
limits. Black bars at the bottom indicate the relative data distribution over the follow-up period. Trajectories of BMI for a hypothetical female of 50
years of age at time of diagnosis are shown in Figure S1. Light blue, stable overweight; dark blue, progressive weight gain; red, persistently obese;
grey, diabetes-free population.
doi:10.1371/journal.pmed.1001602.g002
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Other Characteristics
Among those developing diabetes, a significantly higher
proportion of the persistently obese than the stable overweight
individuals were diagnosed with diabetes by their own general
practitioner (p=0.008) (Table 1). The proportion of women was
also higher in the persistently obese group than in the stable
overweight or diabetes-free groups (p,0.02). Furthermore, indi-
viduals in the stable overweight and progressive weight gain
groups were more likely to have a family history of diabetes
compared with the diabetes-free population (p,0.04) (Table 1).
The characteristics of the participants’ first clinical examination
in the study are shown in Table 2. Since the time span from the
first clinical examination to the diagnosis of diabetes differed
between the groups, the data should not be compared directly.
Time Effects and Posterior Probability Memberships
Estimated beta coefficients (SE) for the time effects are shown in
Table 3. In the stable overweight group, a cubic specification of
time (t3) was only included in the models for fasting and 2-hour
plasma glucose, HOMA-IR, and estimated diabetes and CVD
risk. The trajectories for diastolic blood pressure, cholesterol, and
triglyceride were linear for all groups.
The mean posterior probability of class membership for
individuals was high for each of the classes (75%–96%) (Table 4).
Figure 3. Trajectories for a hypothetical male, not on lipid-lowering treatment, age 60 years at time 0 of total cholesterol (A), HDL
cholesterol (B), LDL cholesterol (C), and triglycerides (D) from 18 years before time of diagnosis/last examination. Solid lines indicate
estimated trajectories for each group and dashed lines are 95% confidence limits. Black bars at the bottom indicate the relative data distribution over
the follow-up period. Light blue, stable overweight; dark blue, progressive weight gain; red, persistently obese; grey, diabetes-free population.
doi:10.1371/journal.pmed.1001602.g003
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Discussion
By use of latent class trajectory analysis we identified three distinct
patterns of obesity development prior to the diagnosis of type 2
diabetes: (1) a stable overweight group, (2) a group of progressive
weight gainers, and (3) a persistently obese group. The patterns of
obesity development were accompanied by different trajectories of
insulin resistance and other cardiometabolic risk factors, under-
scoring that type 2 diabetes is a not a single disease entity, but rather
a heterogeneous disease with different pathophysiological pathways
depending on the level and development of obesity.
In contrast to common belief, the great majority of patients
diagnosed with diabetes did not have a substantial weight gain
prior to diagnosis (stable overweight group). Their average obesity
development was comparable to the reference group not
developing diabetes, with a slightly higher initial BMI level of
1.2 kg/m2 and ending at a 1.9 unit higher BMI level at time of
diagnosis. This group of patients experienced a slightly worsening
of beta cell function and insulin sensitivity starting ,5 years before
they were diagnosed with diabetes. A previous study found that
leaner patients with type 2 diabetes may have a stronger genetic
predisposition than obese patients [20]. Our finding of a higher
proportion of individuals with a family history of diabetes among
the stable overweight group compared with the diabetes-free
group supports this notion. Of particular interest is the finding that
the persistently obese group did not have a higher proportion of
Figure 4. Trajectories for a hypothetical male of 60 years at time 0 of fasting plasma glucose (A), 2-hour plasma glucose (B), fasting
serum insulin (C), and 2-hour serum insulin (D) from 18 years before time of diagnosis/last examination. Solid lines indicate estimated
trajectories for each group and dashed lines are 95% confidence limits. Black bars at the bottom indicate the relative data distribution over the
follow-up period. Light blue, stable overweight; dark blue, progressive weight gain; red, persistently obese; grey, diabetes-free population.
doi:10.1371/journal.pmed.1001602.g004
Obesity Development Prior to Diabetes
PLOS Medicine | www.plosmedicine.org 7 February 2014 | Volume 11 | Issue 2 | e1001602
individuals with a family history of diabetes compared with the
diabetes-free group, which may have prevented them from
developing diabetes earlier in their life despite their high degree
of obesity.
Interestingly, the estimated 8-year diabetes risk from the
Framingham diabetes risk score remained relatively low and even
decreased during the last 5 years prior to diabetes diagnosis in the
stable overweight group. Prediction of diabetes in this group may
therefore be difficult using established validated models. The
finding of a significantly higher proportion of the persistently obese
individuals being diagnosed with diabetes by their own general
practitioner as compared with the two other diabetes groups
supports this notion, and indicates that general practitioners are
more likely to screen for diabetes in morbidly obese than in
overweight individuals. Indeed, our findings support the ‘‘preven-
tion paradox,’’ proposed by Geoffrey Rose more than 30 years
ago, in which he stated that ‘‘a large number of people exposed to
a low risk is likely to produce more cases than a small number of
people exposed to a high risk’’ [21]. In the context of diabetes
prevention, it may therefore not be optimal to focus only on
promoting weight loss in the most obese individuals, but also
aiming at preventing small weight gains in the entire population
(i.e., shifting the entire BMI distribution to the left). This will only
give a small benefit to each individual, but may prove effective at
the population level in terms of preventing diabetes and CVD
events in the future. The progressive weight gainers exhibited a
Figure 5. Trajectories for a hypothetical male of 60 years at time 0 of HOMA-%B (A), HOMA-IR (B), Framingham 8-year diabetes risk
(C), and Framingham 10-year CVD risk (D) from 18 years before time of diagnosis/last examination. Solid lines indicate estimated
trajectories for each group and dashed lines are 95% confidence limits. Black bars at the bottom indicate the relative data distribution over the
follow-up period. Light blue, stable overweight; dark blue, progressive weight gain; red, persistently obese; grey, diabetes-free population.
doi:10.1371/journal.pmed.1001602.g005
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pattern of obesity development with two separate phases of weight
gain before type 2 diabetes diagnosis. Individuals with this pattern
had an exponential increase in both insulin levels and beta cell
function before the diagnosis of diabetes. Of interest, we found
increased IL-1Ra concentrations towards diabetes diagnosis in the
group of progressive weight gainers, but not in the persistently
obese group. A previous analysis of the Whitehall II study found
that IL-1Ra concentrations accelerated 6 years before diagnosis of
diabetes, and differences between individuals who developed
diabetes and those remaining diabetes-free were attenuated by
adjustment for BMI or waist circumference [5]. Comparing
IL-1RA trajectories with concurrent obesity development in our
study, it seems that low-grade inflammation may predominantly
be determined by changes in body weight and to a lesser extent by
changes in glucose metabolism or actual level of obesity. Whether
this applies to the general population needs further investigation.
Figure 6. Trajectories for a hypothetical male of 60 years at time 0 of adiponectin (A) and IL-1Ra (B) from 18 years before time of
diagnosis/last examination. Solid lines indicate estimated trajectories and dashed lines are 95% confidence limits. Black bars at the bottom
indicate the relative data distribution over the follow-up period. Light blue, stable overweight; dark blue, progressive weight gain; red, persistently
obese; grey, diabetes-free population.
doi:10.1371/journal.pmed.1001602.g006
Table 1. Characteristics of study participants at time of diagnosis for the three diabetes groups or at the last
clinical examination for the diabetes-free group.
Characteristics
Individuals Developing Diabetes in the Study Stratified by Latent
Class BMI Groups
Individuals Free of
Diabetes in the Study
Stablen Overweight
(n=604)
Progressive Weight
Gain (n=15)
Persistently Obese
(n=26) Diabetes-Free (n=6,060)
Men (%) 74.5 (70.8–77.9) 53.3 (26.6–78.7) 50.0 (29.9–70.1)a 71.8 (70.6–72.9)b
Ever smoker (%) 56.8 (52.7–60.8) 66.7 (38.4–88.2) 57.7 (36.9–76.6) 51.6 (50.3–52.8)a
Family history of diabetes (%) 19.9 (16.8–23.3) 26.7 (7.8–55.1) 11.5 (2.4–30.2) 9.8 (9.1–10.6)a,c
Diagnosed by GP outside study (%) 42.2 (38.2–46.3) 33.3 (11.8–61.6) 69.2 (48.2–85.7)a,c –
Ever on anti-hypertensive treatment (%) 27.6 (24.1–31.4) 20.0 (4.3–48.1) 38.5 (20.2–59.4) 22.9 (21.9–24.0)a
Ever on lipid lowering treatment (%) 14.4 (11.7–17.5) 13.3 (1.7–40.5) 15.4 (4.4–34.9) 15.7 (14.8–16.7)
Age at diagnosis/last exam. (years) 60.6 (7.8) 61.1 (8.2) 57.9 (7.7) 60.3 (7.9)
Data are percentages (95% CI) or means (SD). Test of difference in characteristics between groups: chi-square test for categorical variables and t-test for continuous
data, respectively.
Significantly different.
aSignificantly different from stable overweight.
bSignificantly different from persistently obese.
cSignificantly different from progressive weight gain.
doi:10.1371/journal.pmed.1001602.t001
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Despite an increase in both obesity and systolic blood pressure
over time, the calculated 10-year CVD risk from the Framingham
CVD risk score was lower among the progressive weight gainers
than among the other two groups at time of diabetes diagnosis,
whereas the persistently obese and stable overweight groups had
similar levels of estimated CVD risk despite different trajectories of
CVD risk factors. These findings question the validity of calculated
scores for disease risk in a population with heterogeneous disease
development. Thus, future risk prediction models should aim to
include knowledge about the heterogeneity of disease development
instead of assuming a one-size-fits-all model.
The group of persistently obese individuals was on average
characterised by class II obesity (35–40 kg/m2) [22] already 18
years before they were diagnosed with type 2 diabetes. Towards
diabetes diagnosis this group experienced a pattern of beta cell
compensation followed by loss of beta cell function, whereas
insulin resistance only increased slightly. This pattern of beta cell
dysfunction has for many years been thought to be characteristic
for type 2 diabetes development [23]. However, this suggestion
was originally based on a cross-sectional study of 82 individuals with
long-standing (,8–32 years) obesity and ,8 years duration of type
2 diabetes [24], which questions the generalizability to leaner
individuals with newly diagnosed diabetes. Thus, as evident from
our data, the natural history of beta cell dysfunction in type 2
diabetes seems to be even more complex than previously thought
and indeed not similar in all people developing type 2 diabetes [25].
A major strength of the Whitehall II study is its 18-year follow-
up period and the detailed phenotypic characterisation of the
study participants, which enabled us to relate trajectories of obesity
development to trajectories of clinically relevant measures of
metabolism and cardiovascular risk. Most previous studies
examining BMI development over time have assumed that there
is an average pattern of obesity development over time applying to
the whole population [11,26–28]. Another often used approach is
to classify BMI into pre-defined categories, as currently debated in
relation to mortality [29]. Limitations of this approach are that
available information is not utilised optimally [30], and it may
cause misclassification of individuals, especially near the cut-points
Table 2. Characteristics of study participants at their first clinical examination.
Characteristics
Individuals Developing Diabetes in the Study Stratified by Latent
Class BMI Groups
Individuals Free of
Diabetes in the Study
Stable Overweight
(n=604)
Progressive Weight
Gain (n=15)
Persistently Obese
(n=26)
Diabetes-Free
(n=6,060)
Time before diabetes diagnosis/last
examination (years)
10.3 (5.6–12.7) 6.6 (5.0–13.0) 10.9 (9.7–15.2) 14.3 (9.0–16.2)
Men (%) 74.5 (70.8–77.9) 53.3 (26.6–78.7) 50 (29.9–70.1)a 71.8 (70.6–72.9)b
Smoker (%) 14.9 (12.2–18.0) 13.3 (1.7–40.5) 23.1 (9.0–43.6) 12.0 (11.2–12.9)a
Family history of diabetes (%) 19.9 (16.8–23.3) 26.7 (7.8–55.1) 11.5 (2.4–30.2) 9.8 (9.1–10.6)a,c
Antihypertensive treatment (%) 14.6 (11.9–17.6) 6.7 (0.2–31.9) 23.1 (9.0–43.6) 8.5 (7.9–9.3)a,b
Lipid lowering treatment (%) 4.5 (3.0–6.4) 0 0 2.4 (2.0–2.8)a
Age (years) 52.7 (7.0) 52.9 (7.3) 50.0 (5.9) 51.6 (7.4)a
Fasting plasma glucose (mmol/l) 5.7 (1.1) 5.6 (1.5) 5.6 (0.7) 5.2 (0.5)a,b,c
2-hour plasma glucose (mmol/l) 6.6 (2.3) 7.1 (3.0) 6.6 (2.1) 5.2 (1.4)a,b,c
BMI (kg/m2) 27 (3.8) 34.2 (8.7)a 38.2 (5.0)a,c 25.3 (3.6)a,b,c
Waist circumference (cm) 92.3 (11.8) 99.6 (18.0)a 112.0 (10.9)a,c 86.8 (11.7)a,b,c
Height (cm) 172.4 (9.1) 167.4 (9.4)a 166.5 (10.4)a 172.9 (9.1)b,c
Total cholesterol (mmol/l) 6.6 (1.2) 6 (1.2) 6.8 (1.0)c 6.3 (1.2)a,b
HDL cholesterol (mmol/l) 1.3 (0.4) 1.3 (0.2) 1.2 (0.4) 1.5 (0.4)a,b
LDL cholesterol (mmol/l) 4.4 (1) 3.9 (1.1) 4.5 (0.9) 4.2 (1.1)a
Triglycerides (mmol/l) 1.9 (1.3) 1.8 (0.6) 2.8 (2.1)a,c 1.3 (0.9)a,b
Systolic blood pressure (mmHg) 125.4 (15.5) 122.7 (22.3) 128.0 (14.9) 120.6 (14.3)a,b
Diastolic blood pressure (mmHg) 81.4 (10.3) 80.1 (14.1) 85.5 (9.7)a 78.1 (9.9)a,b
Fasting serum insulin (pmol/l) 8.5 (5.4–13.3) 12.5 (7.5–31.5)a 15.9 (10.2–20.7)a 5.8 (3.9–8.7)a,b,c
2-hour serum insulin (pmol/l) 52.0 (29.4–86.4) 56.5 (46.9–96.5) 84.3 (44.8–140.7)a 30.6 (17.6–50.8)a,b,c
HOMA-IR 2.2 (1.4–3.5) 3.2 (1.9–7.3)a 3.8 (2.5–5.2)a 1.5 (1.0–2.2)a,b,c
HOMA-%B 86.4 (60.5–131.5) 132.8 (123.7–153.3)a 155.5 (109.4–214.8)a 77.3 (56–112)a,b,c
Adiponectin (mg/ml) 7.4 (5.3–10.8) 7.4 (7.0–9.7) 7.9 (5.0–12.6) 9.0 (6.6–12.8)a
CRP (mmol/L) 1.3 (0.7–2.6) 1.8 (1.4–3.2) 4.4 (2.4–6.6)a 0.8 (0.4–1.7)a,b,c
IL-6 (mmol/l) 1.6 (1.2–2.3) 1.6 (1.1–3) 2.5 (2.1–3.8)a 1.3 (1.0–2.0)a,b
Data are percentages (95% CI), means (SD) or medians (IQR). Test of difference in characteristics between groups: chi-square test for categorical variables and t-test for
continuous data, respectively.
aSignificantly different from stable overweight.
bSignificantly different from persistently obese.
cSignificantly different from progressive weight gain.
doi:10.1371/journal.pmed.1001602.t002
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for classification [31]. Moreover, the use of such more or less
arbitrarily set cut-points keeps research locked in pre-defined
concepts and thought patterns, which may prevent research
moving forward. Instead of studying changes in predefined BMI
categories, we chose to define subgroups of individuals by latent
class trajectory analysis. This type of statistical method is useful to
explore heterogeneous growth patterns that would not be
identified by use of conventional methods. Indeed, latent class
trajectory analysis is more flexible, because it models group-
specific average patterns of obesity development. One disadvan-
tage of latent class analysis is, however, that it often results in very
different sizes of subgroups [11,32], potentially limiting statistical
power as well as interpretation and generalizability of the results.
Another factor limiting the generalizability of our results is that
this analysis was performed only in white participants. The reason
for studying obesity development in an ethnically homogenous
population was to avoid identifying differences in BMI patterns
mainly attributed to ethnic differences. Therefore, these analyses
should be confirmed in other study populations. In conclusion,
latent class trajectory analysis identified three distinct patterns of
obesity development leading to type 2 diabetes. The accompany-
ing trajectories of insulin resistance and other cardiometabolic risk
factors differed between these groups. In general, the majority of
individuals developing type 2 diabetes were rather weight stable
during follow-up with a slightly higher average BMI than the
diabetes-free population, suggesting that strategies focusing on
small weight reductions for the entire population may be more
beneficial than predominantly focusing on weight loss for high-risk
individuals.
Supporting Information
Figure S1 Trajectories for a hypothetical female of 50
years at time 0 of body mass index from 18 years before
time of diagnosis/last examination. Solid lines indicate
estimated trajectories for each group and dashed lines are 95%
confidence limits. Black bars at the bottom indicate the relative
data distribution over the follow-up period. Light blue, stable
overweight; dark blue, progressive weight gain; red, persistently
obese; grey, diabetes-free population.
(TIF)
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Editors’ Summary
Background.Worldwide, more than 350million people have
diabetes, a metabolic disorder characterized by high amounts
of glucose (sugar) in the blood. Blood sugar levels are
normally controlled by insulin, a hormone released by the
pancreas after meals (digestion of food produces glucose). In
people with type 2 diabetes (the commonest form of
diabetes) blood sugar control fails because the fat and muscle
cells that normally respond to insulin by removing sugar from
the blood become insulin resistant. Type 2 diabetes, which
was previously called adult-onset diabetes, can be controlled
with diet and exercise, and with drugs that help the pancreas
make more insulin or that make cells more sensitive to insulin.
Long-term complications, which include an increased risk of
heart disease and stroke, reduce the life expectancy of people
with diabetes by about 10 years compared to people without
diabetes. The number of people with diabetes is expected to
increase dramatically over the next decades, coinciding with
rising obesity rates in many countries. To better understand
diabetes development, to identify people at risk, and to find
ways to prevent the disease are urgent public health goals.
Why Was This Study Done? It is known that people who
are overweight or obese have a higher risk of developing
diabetes. Because of this association, a common assumption is
that people who experienced recent weight gain are more
likely to be diagnosed with diabetes. In this prospective cohort
study (an investigation that records the baseline characteristics
of a group of people and then follows them to see who
develops specific conditions), the researchers tested the
hypothesis that substantial weight gain precedes a diagnosis
of diabetes and explored more generally the patterns of body
weight and composition in the years before people develop
diabetes. They then examinedwhether changes in body weight
corresponded with changes in other risk factors for diabetes
(such as insulin resistance), lipid profiles and blood pressure.
What Did the Researchers Do and Find? The researchers
studied participants from the Whitehall II study, a prospective
cohort study initiated in 1985 to investigate the socioeco-
nomic inequalities in disease. Whitehall II enrolled more than
10,000 London-based government employees. Participants
underwent regular health checks during which their weight
and height were measured, blood tests were done, and they
filled out questionnaires for other relevant information. From
1991 onwards, participants were tested every five years for
diabetes. The 6,705 participants included in this study were
initially free of diabetes, and most of them were followed for
at least 14 years. During the follow-up, 645 participants
developed diabetes, while 6,060 remained free of the disease.
The researchers used a statistical tool called ‘‘latent class
trajectory analysis’’ to study patterns of changes in body
mass index (BMI) in the years before people developed
diabetes. BMI is a measure of human obesity based on a
person’s weight and height. Latent class trajectory analysis is
an unbiased way to subdivide a number of people into
groups that differ based on specified parameters. In this
case, the researchers wanted to identify several groups
among all the people who eventually developed diabetes
each with a distinct pattern of BMI development. Having
identified such groups, they also examined how a variety of
tests associated with diabetes risk, and risks for heart disease
and stroke changed in the identified groups over time.
They identified three different patterns of BMI changes in the
645 participants who developed diabetes. The vast majority
(606 individuals, or 94%) belonged to a group they called
‘‘stable-overweight.’’ These people showed no dramatic
change in their BMI in the years before they were diagnosed.
They were overweight when they first entered the study and
gained or lost little weight during the follow-up years. They
showed only minor signs of insulin-resistance, starting five
years before they developed diabetes. A second, much smaller
group of 15 people gained weight consistently in the years
before diagnosis. As they were gaining weight, these people
also had raises in blood pressure and substantial gains in insulin
resistance. The 26 remaining participants who formed the third
group were persistently obese for the entire time they
participated in the study, in some cases up to 18 years before
they were diagnosed with diabetes. They had some signs of
insulin resistance in the years before diagnosis, but not the
substantial gain often seen as the hallmark of ‘‘pre-diabetes.’’
What Do These Findings Mean? These results suggest
that diabetes development is a complicated process, and
one that differs between individuals who end up with the
disease. They call into question the common notion that
most people who develop diabetes have recently gained a
lot of weight or are obese. A substantial rise in insulin
resistance, another established risk factor for diabetes, was
only seen in the smallest of the groups, namely the people
who gained weight consistently for years before they were
diagnosed. When the scientists applied a commonly used
predictor of diabetes called the ‘‘Framingham diabetes risk
score’’ to their largest ‘‘stably overweight’’ group, they found
that these people were not classified as having a particularly
high risk, and that their risk scores actually declined in the
last five years before their diabetes diagnosis. This suggests
that predicting diabetes in this group might be difficult.
The researchers applied their methodology only to this one
cohort of white civil servants in England. Before drawing more
firm conclusions on the process of diabetes development, it will
be important to test whether similar results are seen in other
cohorts and amongmore diverse individuals. If the three groups
identified here are found in other cohorts, another question is
whether they are as unequal in size as in this example. And if
they are, can the large group of stably overweight people be
further subdivided in ways that suggest specific mechanisms of
disease development? Even without knowing how generaliz-
able the provocative findings of this study are, they should
stimulate debate on how to identify people at risk for diabetes
and how to prevent the disease or delay its onset.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001602.
N The US National Diabetes Information Clearinghouse
provides information about diabetes for patients, health-
care professionals, and the general public, including
information on diabetes prevention (in English and Spanish)
N The UK National Health Service Choices website provides
information for patients and carers about type 2 diabetes;
it includes people’s stories about diabetes
N The charity Diabetes UK also provides detailed information
about diabetes for patients and carers, including information
on healthy lifestyles for people with diabetes, and has a
further selection of stories from people with diabetes; the
charity Healthtalkonline has interviews with people about
their experiences of diabetes
N MedlinePlus provides links to further resources and advice
about diabetes (in English and Spanish)
N More information about the Whitehall II study is available
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